The concise synthesis of a key intermediate for the total synthesis of fumagillin, TNP-470, and ovalicin

Synthesis

Volumn , Issue 9, 2008, Pages 1460-1466

  Yadav, Jhillu S ^a   Sreedhar, Pamu ^a   Srihari, Pabbaraja ^a   Sarma, Ganti Dattatreya ^a   Jagadeesh, Bharatam ^a  

^a INDIAN INSTITUTE OF CHEMICAL TECHNOLOGY   (India)

Author keywords

Angiogenesis inhibitors; Diels alder reaction; Dihydroxylation; HIV; Syn reduction

Indexed keywords

CYCLOHEXANE; REACTION KINETICS; REDUCTION; SYNTHESIS (CHEMICAL); ZINC;

ANGIOGENESIS INHIBITORS; DIELS-ALDER REACTIONS; DIHYDROXYLATION; SYN REDUCTION;

ANTIBIOTICS;

1,3 DIOXOLANE DERIVATIVE; 4 (HYDROXYMETHYL) 2,2 DIMETHYLHEXAHYDROBENZO 1,3 DIOXOLE 5 SPIRO 4' (2,2 DIMETHYL 1,3 DIOXOLANE); ANGIOGENESIS INHIBITOR; FUMAGILLIN; FUMAGILLOL CHLOROACETYLCARBAMATE; OVALICIN;

AROMATIZATION; ARTICLE; BROMINATION; DIELS ALDER REACTION; DRUG STRUCTURE; DRUG SYNTHESIS; EPOXIDATION; HYDROGENATION; HYDROXYLATION; MASS SPECTROMETRY; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; ONE POT SYNTHESIS; RING OPENING;

EID: 44049095593     PISSN: 00397881     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2008-1067030     Document Type: Article

References (73)

1. (a) Hanahan, D.; Folkman, J. Cell 1996, 86, 353.
2. (b) Folkman, J. Nat. Med. 1995, 1, 27.
3. (c) Folkman, J.; Klagsbrun, M. Science 1987, 235, 442.
4. (d) McCowen, M. C.; Callender, M. E.; Lawlis, J. F. Science 1951, 113, 202.
5. (a) Powell, D.; Skotnicki, J.; Upeslacis, J. Annu. Rep. Med. Chem. 1997, 32, 161.
6. (b) Giannis, A.; Rubsam, F. Angew. Chem., Int. Ed. Engl. 1997, 36, 588.
7. (c) Auerbach, W.; Auerbach, R. Pharmacol. Ther. 1994, 63, 265.
8. (d) Folkman, J. N. Engl. J. Med. 1971, 285, 1182.
9. (a) Killough, J. H.; Magill, G. B.; Smith, R. C. Science 1952, 115, 71.
10. (b) Katznelson, H.; Jamieson, C. A. Science 1952, 115, 70.
11. (c) See also ref. 1d.
12. (d) Eble, T. E.; Hanson, F. R. Antibiot. Chemother. (Washington, D.C.) 1951, 1, 54.
13. (a) Asami, Y.; Kakeya, H.; Onose, R.; Chang, Y.-H.; Toi, M.; Osada, H. Tetrahedron 2004, 60, 7085.
14. (b) Yamaguchi, J.; Toyoshima, M.; Shoji, M.; Kakeya, H.; Osada, H.; Hayashi, Y. Angew. Chem. Int. Ed. 2006, 45, 789.
15. (a) O'Reilly, M. S.; Boehm, T.; Shing, Y.; Fukai, N.; Vasios, G.; Lane, W. S.; Flynn, E.; Birkhead, J. R.; Olsen, B. R.; Folkman, J. Cell 1997, 88, 277.
16. (b) Oh, S. P.; Warman, M. L.; Seldin, M. F.; Cheng, S. D.; Knoll, J. H. M.; Timmons, S.; Olsen, B. R. Genomics 1994, 19, 494.
17. (a) O'Reilly, M. S.; Holmgren, L.; Shing, Y.; Chen, C.; Rosenthal, R. A.; Moses, M.; Lane, W. S.; Cao, Y.; Sage, E. H.; Folkman, J. Cell 1994, 79, 315.
18. (b) Gately, S.; Twardowski, P.; Stack, M. S.; Patrick, M.; Boggio, L.; Cundiff, D. L.; Schnaper, H. W.; Madison, L.; Volpert, O.; Bouck, N.; Enghild, J.; Kwaan, H. C.; Soff, G. A. Cancer Res. 1996, 56, 4887.
19. (a) Sigg, H. P.; Weber, H. P. Helv. Chim. Acta 1968, 51, 1395.
20. (b) Sassa, T.; Kaise, H.; Munata, K. Agric. Biol. Chem. 1970, 34, 649.
21. (c) Corey, E. J.; Dittami, J. P. J. Am. Chem. Soc. 1985, 107, 256.
22. (d) Tiefenbacher, K.; Arion, V. B.; Mulzer, J. Angew. Chem. Int. Ed. 2007, 46, 1.
23. (a) Ingber, D.; Fujita, T.; Kishimoto, S.; Sudo, K.; Kanamaru, T.; Brem, H.; Folkman, J. Nature 1990, 348, 555.
24. (b) Figg, W. D.; Kruger, E. A. Expert Opin. Invest. Drugs 2000, 9, 1383.
25. (c) Kwon, J.; Jeong, H.; Kang, K.; Hang, Y.; Bae, K.; Choi, J.; Lee, U.; Son, K.; Kown, B. J. Antibiot. 2000, 53, 799.
26. (a) See also ref. 3b.
27. (b) See also ref. 3a.
28. (c) Zhang, P.; Nicholson, D. E.; Bujnicki, J. M.; Su, X.; Brendle, J. J.; Ferdig, M.; Kyle, D. E.; Milhous, W. K.; Chiang, P. K. J. Biomed. Sci. 2002, 9, 34.
29. (a) Molina, J. M.; Derouin, F. PCT Int. Appl. WO 9630010, 1996; Chem. Abstr. 1996, 125, 309073.
30. (b) Coyle, C.; Kent, M.; Tanowitz, H. B.; Wittner, M.; Weiss, L. M. J. Infect. Dis. 1998, 177, 515.
31. (c) Molina, J. M.; Goguel, J.; Sarfati, C.; Michiels, J.-F.; Desportes-Livage, I.; Balkan, S.; Chastang, C.; Cotte, L.; Maslo, C.; Struxiano, A.; Derouin, F.; Decazes, J.-M. AIDS 2000, 14, 1341.
32. Watanabe, N.; Nishihara, Y.; Yamaguchi, T.; Koito, A.; Miyoshi, H.; Kakeya, H.; Osada, H. FEBS Lett. 2006, 580, 2598.
33. Corey, E. J.; Snider, B. B. J. Am. Chem. Soc. 1972, 94, 2549.
34. For the total synthesis of fumagillin and the synthesis of its key intermediate fragments and some other analogues, see: (a) Camara, F.; Angarita, J.; Mootoo, D. R. J. Org. Chem. 2005, 70, 6870.
35. (b) Ciampini, M.; Perlmutter, P.; Watson, K. Tetrahedron: Asymmetry 2007, 18, 243.
36. (c) Bedel, O.; Haudrechy, A.; Pouilhes, A.; Langlois, Y. Pure Appl. Chem. 2005, 77, 1139.
37. (d) Manitschek, R.; Huwe, A.; Giannis, A. Org. Biomol. Chem. 2005, 3, 2150.
38. (e) Vosburg, D. A.; Weiler, S.; Sorensen, E. Chirality 2003, 15, 156.
39. (f) Picoul, W.; Bedel, O.; Haudrechy, A.; Langlois, Y. Pure Appl. Chem. 2003, 75, 235.
40. (g) Fardis, M.; Pyun, H. J.; Tario, J.; Jin, H. L.; Kim, C. U.; Ruckman, J.; Lin, Y.; Green, L.; Hicke, B. Bioorg. Med. Chem. 2003, 11, 5051.
41. (h) Picoul, W.; Urchequi, R.; Haudrechy, A.; Langlois, Y. Tetrahedron Lett. 1999, 40, 4797.
42. (i) Taber, D. F.; Christos, T. E.; Rheingold, A. L.; Guzei, I. A. J. Am. Chem. Soc. 1999, 121, 5589.
43. (j) Hutchings, M.; Moffat, D.; Simpkins, N. S. Synlett 2001, 661.
44. (k) Kim, D.; Ahn, S. K.; Bae, H.; Choi, W. J.; Kim, H. S. Tetrahedron Lett. 1997, 38, 4437.
45. (l) Vosburg, D. A.; Weiler, S.; Sorensen, E. J. Angew. Chem. Int. Ed. 1999, 38, 971.
46. (m) Bedel, O.; Haudrechy, A.; Langlois, Y. Eur. J. Org. Chem. 2004, 3813.
47. (n) Boiteau, J.-G.; Van de Weghe, P.; Eustache, J. Org. Lett. 2001, 3, 2737.
48. (a) Yadav, J. S.; Sreedhar, P.; Bhunia, D. C.; Srihari, P. Synlett 2007, 992.
49. For our other contributions toward the synthesis of biologically active natural products, see: (b) Yadav, J. S.; Chetia, L. Org. Lett. 2007, 9, 4587.
50. (c) Yadav, J. S.; Pratap, T. V.; Rajender, V. J. Org. Chem. 2007, 72, 5882.
51. (d) Srihari, P.; Prem Kumar, B.; Subbarayudu, K.; Yadav, J. S. Tetrahedron Lett. 2007, 48, 6977.
52. (e) Yadav, J. S.; Prathap, I.; Tadi, B. P. Tetrahedron Lett. 2006, 47, 3773.
53. (f) Yadav, J. S.; Srinivas, R.; Sathaiah, K. Tetrahedron Lett. 2006, 47, 1603.
54. (g) Yadav, J. S.; Raju, A. K.; Rao, P. P.; Rajaiah, G. Tetrahedron: Asymmetry 2005, 16, 3283.
55. ( h) Yadav, J. S.; Prakash, S. J.; Gangadhar, Y. Tetrahedron: Asymmetry 2005, 16, 2722.
56. (i) Yadav, J. S.; Reddy, M. S.; Prasad, A. R. Tetrahedron Lett. 2005, 46, 2133.
57. Leroy, J. Synth. Commun. 1992, 22, 567.
58. Regiospecificity was determined by comparing the corresponding reactions of furfuryl alcohols with different protecting groups and studying their stereochemistry by NMR spectroscopic methods. When TBS protection was used, a mixture of isomers was formed; however, with a PMB protecting group, only one regioisomer was synthesized, see: Nelson, W. L.; Allen, D. R. Heterocycl. Chem. 1972, 9, 561.
59. Leroy, J. Tetrahedron Lett. 1992, 33, 2969.
60. 2O. However, a prolonged reaction time with Pd/C also resulted in the saturated PMB-deprotected product.
61. (a) Bernet, B.; Vasella, A. Helv. Chim. Acta 1979, 62, 1990.
62. For applications and modified procedures, see: (b) Ferrier, R. J.; Furneaux, R. H.; Prasit, P.; Tyler, P. C.; Brown, K. L.; Gainsford, G. J.; Diehl, W. J. Chem. Soc., Perkin Trans. 1 1983, 1621.
63. (c) Ferrier, R. J.; Prasit, P. J. Chem. Soc., Perkin Trans. 1 1983, 1645.
64. ( d) Ferrier, R. J.; Schmidt, P.; Tyler, P. C. J. Chem. Soc., Perkin Trans. 1 1985, 301.
65. (e) Nicolaou, K. C.; Duggan, M. E.; Ladduwahetty, T. Tetrahedron Lett. 1984, 25, 2069.
66. (f) Yadav, J. S.; Reddy, B. V. S.; Srinivasa Reddy, K. Tetrahedron 2003, 59, 5333.
67. (g) See also ref. 14a.
68. 2;
69. 2;
70. 2O;
71. 2.
72. Molecules with a similar core including an epoxide moiety were found to be biologically active, see: Mazitschek, R.; Huwe, A.; Giannis, A. Org. Biomol. Chem. 2995, 3, 2150.
73. 1,2-Asymmetric syn reduction was achieved by following a known protocol used for the stereoselective reduction of β-hydroxy ketone, see: Narasaka, K.; Pai, F.-C. Tetrahedron 1984, 40, 2233.